TELA Bio, Inc. (TELA) Stock Forecast
TELA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 6 analysts
- Price target
- $1.90 average of analyst targets
- Upside to target
- +94.9% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.19
- 52-week range
- $0.56 – $1.51
TELA analyst ratings
6 analystsNumber of analysts at each rating.
TELA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TELA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.16 | −$0.21 | −$0.13 | −$0.19 | +15.8% | 5 |
| Current fiscal year (2026) | −$0.70 | −$0.76 | −$0.66 | −$0.83 | +15.7% | 5 |
| Next fiscal year (2027) | −$0.45 | −$0.52 | −$0.40 | −$0.70 | +35.1% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TELA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $20.0M | $18.9M | $20.8M | −3.4% | 5 |
| Current fiscal year (2026) | $79.5M | $77.6M | $80.6M | −1.0% | 5 |
| Next fiscal year (2027) | $86.3M | $82.9M | $89.3M | +8.6% | 5 |
TELA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TELA revenue: reported and forecast
TELA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.15 | −$0.16 | −$0.15 | −$0.16 | +6.7% | 3 up · 2 down |
| Current fiscal year (2026) | −$0.67 | −$0.70 | −$0.69 | −$0.69 | −$0.70 | +4.8% | 1 up · 4 down |
| Next fiscal year (2027) | −$0.56 | −$0.52 | −$0.46 | −$0.45 | −$0.45 | −18.3% | 5 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TELA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TELA beat in 3 of 12.
What analysts expect from TELA
6 analysts cover TELA Bio; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.90, 94.9% above the latest close of $0.97. Analysts expect earnings of −$0.70 per share for 2026, +15.7% from a year earlier. For 2027 the average estimate is −$0.45 per share on revenue of $86.3 million. TELA Bio beat the EPS estimate in 3 of the last 12 quarters.
Related: TELA income statement, TELA key metrics, TELA chart. See the TELA stock overview for the latest quote and news.
TELA forecast FAQ
What is TELA Bio's price target?
The average analyst price target for TELA Bio is $1.90, 94.9% above the latest close of $0.97.
Is TELA Bio a buy, hold or sell?
Of 6 analysts covering TELA Bio, 4 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is TELA Bio's EPS forecast?
Analysts forecast −$0.70 per share for 2026 (range −$0.76 to −$0.66); for 2027 the estimate is −$0.45.
What is TELA Bio's revenue forecast?
The average revenue estimate for 2026 is $79.5 million, growth of −1.0%; for 2027 it is $86.3 million.
When does TELA Bio report earnings?
TELA Bio is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.19.
Does TELA Bio usually beat earnings estimates?
TELA Bio reported EPS at or above the analyst estimate in 3 of the last 12 quarters.